Cash Application Manager

Kestra appoints Curtis Kopf as Senior Vice President of Customer Experience. KIRKLAND, Wash., Aug. 26, 2026 (GLOBE NEWSWIRE) - Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced the appointment of Curtis Kopf as Senior Vice President of Customer Experience. In this newly created role, Mr. Kopf will lead the patient experience from approval of a patient order through completion of therapy and device return, aligning the people, processes and technology that support providers and their patients throughout the use of the ASSURE(R) WCD. "Our mission is to provide innovative, intuitive medical technologies to protect and support at-risk patients. That mission guides both the technology we create and the experience we deliver, helping patients begin therapy with confidence and remain engaged, connected, and protected throughout their care," said Brian Webster, President and Chief Executive Officer. "Curtis brings the vision and experience to lead that journey end to end, harnessing data and automation to scale patient support, strengthen performance at every stage, and extend the impact of the ASSURE WCD and the broader Cardiac Recovery System platform to more patients." Mr. Kopf has extensive experience leading customer experience, digital transformation, and large-scale service operations. Most recently, he served as Group Vice President, Global Customer Experience at Insulet Corporation, where he led a global organization of more than 1,000 employees across digital, customer service, and customer success and helped advance the adoption of artificial intelligence across a large-scale service organization. Previously, he served as Chief Experience Officer and Chief Digital Officer at REI, where he led customer experience, digital, analytics, innovation, and service organizations. "Every interaction is an opportunity to build confidence, remove friction, and help patients stay connected throughout their cardiac recovery," said Mr. Kopf. "Kestra has built a powerful combination of differentiated technology and deeply committed patient support. I look forward to working with the team to anticipate patient needs, simplify each step of the journey, and scale that experience while preserving the human connection that matters most." The appointment of Mr. Kopf comes as Kestra invests in its commercial capabilities, including multiple artificial intelligence initiatives designed to drive operating leverage across its customer-facing operations. These investments are expected to position Kestra for its next stage of growth by advancing the technology that protects patients and the experience that supports them. About Kestra Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. Media contact Rhiannon Pickus [email protected] Investor contact Neil Bhalodkar [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Alabama Business Reporter do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Kestra Medical (KMTS) grew fast in FY2026, but cash discipline still matters. What KMTS reported in the latest quarter or fiscal year. Kestra Medical Technologies closed fiscal 2026 with the kind of top-line growth that keeps investors engaged, but the latest results still show a business being built ahead of profitability. In the July 14 earnings release attached to Kestra's Form 8-K, the company said fourth-quarter fiscal 2026 revenue rose 66% year over year to $28.6 million, while full-year revenue increased 59% to $95.1 million. Gross profit also improved meaningfully, with fourth-quarter gross margin expanding to 54.8% from 44.3% a year earlier and full-year gross margin reaching 51.4% from 40.5%. The same release showed why the equity story remains a scale-and-execution story rather than an earnings story. Fourth-quarter GAAP operating expenses were $55.0 million, roughly flat with the prior year period, but still almost twice quarterly revenue. For the full year, GAAP operating expenses rose to $183.6 million from $130.6 million in fiscal 2025 as Kestra continued to invest in commercial expansion. That left the company with a fourth-quarter GAAP net loss of $38.8 million and a full-year GAAP net loss of $131.6 million. Discover more Industry news digests Those figures make the latest report more nuanced than a plain "revenue beat" read. Kestra is proving it can grow the wearable cardioverter-defibrillator business quickly, but it has not yet shown that growth can absorb the commercial cost base on its own. What management's earnings discussion says about growth and adoption. Management's commentary stayed tightly focused on adoption of the ASSURE wearable cardioverter-defibrillator system. Kestra said 6,357 ASSURE prescriptions were written in the fourth quarter, up 63% from the prior year period. Full-year prescriptions rose 57% to 20,720. In the release, management attributed revenue growth primarily to higher market share, broader wearable cardioverter-defibrillator market expansion, a higher mix of in-network patients, and improvements in revenue-cycle management. That matters because prescription growth is the clearest operating proof point in this business model. Revenue can benefit from billing mix and collections timing, but sustained prescription growth says physicians are actually putting the device into use. The fourth-quarter prescription growth rate running ahead of the full-year growth rate also suggests momentum did not fade into year-end. Discover more Stocks & Bonds Investment strategy guides President and CEO Brian Webster used the release to frame fiscal 2026 as more than a sales-growth year. He pointed to rapid growth of the commercial organization, primary results from the FDA post-approval study, the launch of the latest algorithm update, and a strategic collaboration with Biobeat Technologies. None of those milestones automatically converts into near-term revenue, but together they show management trying to widen the company's moat through clinical validation, product performance, and workflow expansion instead of relying only on more sales reps. The key investor takeaway from the latest earnings discussion is that Kestra is trying to move from being a promising challenger into being a better-established platform in a market where credibility, reimbursement execution, and physician adoption all matter. Cash runway, margins, and execution risks investors should watch. The financial release and related filings also make clear why liquidity still sits at the center of the investment debate. Kestra reported cash, cash equivalents, and investments of $262.2 million as of April 30, 2026. That headline figure matters more than the cash-and-cash-equivalents line alone because the company added short-term and long-term investments during the year. The cash-flow statement in the 10-K shows net cash used in operating activities of $81.7 million in fiscal 2026, compared with $77.6 million in fiscal 2025. That burn rate is real, but the company moved to strengthen the balance sheet before reporting results. A July 10 Form 8-K disclosed a five-year senior secured term loan facility of up to $200.0 million. The structure includes a funded $75.0 million Tranche A loan, a committed $25.0 million Tranche B loan available through July 31, 2027 subject to conditions, a committed $50.0 million Tranche C loan tied to a trailing 12-month revenue milestone of $150.0 million, and an uncommitted $50.0 million acquisition tranche. The same filing said the borrower must maintain minimum liquidity of at least $20.0 million in cash and cash equivalents at all times. Discover more Company profile database Earnings call transcripts Investment research tools That financing helps, but it does not erase the execution burden. The debt comes with interest, covenants, and a secured claim on substantially all company assets. Investors should also watch whether gross-margin gains keep holding as volumes rise. Kestra's fourth-quarter gross margin of 54.8% and full-year gross margin of 51.4% show that scale is helping at the product level. The question now is whether the company can keep that margin progress while slowing the pace of operating-expense growth enough to narrow losses more decisively. What the latest KMTS earnings discussion means for the next few quarters. The clearest near-term marker is management's fiscal 2027 revenue guidance of $137 million, which implies 44% growth from fiscal 2026. That is still a high-growth target, but it is also a step down from the 59% growth the company just posted for fiscal 2026. In other words, Kestra is now being asked to prove it can keep growing at a strong rate while gradually becoming more efficient. The next few quarters should therefore be judged on three linked signals. First, prescription growth needs to remain strong enough to support the fiscal 2027 revenue target. Second, gross margin needs to stay above the 50% level to show the business is not buying growth at deteriorating unit economics. Third, operating cash burn needs to improve enough that the new credit facility looks like opportunistic balance-sheet support rather than a sign the business needs constant external funding. The latest earnings discussion does not change the core KMTS thesis. Kestra still has a real growth story, backed by improving gross margin and rising ASSURE prescription volume. But it also remains a company whose valuation and investor confidence will depend on turning commercial momentum into a more durable financial profile. For the next few quarters, KMTS looks less like a simple revenue-growth story and more like a test of whether a fast-scaling medtech challenger can grow into its cost structure before financing becomes the main narrative. Key signals for investors. * Fourth-quarter fiscal 2026 revenue rose 66% to $28.6 million, so investors should watch whether that growth rate can stay strong enough to support the $137 million fiscal 2027 revenue target. * Full-year gross margin improved to 51.4% from 40.5%, making margin retention above 50% a key test of whether scale is improving unit economics. * Full-year prescriptions increased 57% to 20,720, which makes future prescription growth the cleanest operating signal for whether adoption momentum is holding. * Fiscal 2026 net cash used in operating activities was $81.7 million, so quarterly cash burn remains central to judging how much flexibility the new credit facility really provides. * The new loan agreement adds up to $200.0 million of financing capacity, but the liquidity covenant and secured structure mean balance-sheet support now comes with tighter execution expectations.